Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
- To find out if the chemotherapy treatment using Pemetrexed (Alimta) and Oxaliplatin
(Eloxatin) given together will kill the cancer cells in the patient's body and shrink
the size of their tumor. This may allow patients to live longer or decrease the
frequency and/or severity of the symptoms caused by the cancer. Pemetrexed has been
approved by the Food and Drug Administration (FDA) to treat Lung Cancer. Oxaliplatin has
been approved by the FDA for the treatment of Colon Cancer. The combination of these two
drugs has been used to treat patients with Non-Small Cell Lung Cancer in Italy but not
yet in the USA
Other purposes of this study are:
- To better detail the toxic effects of this chemotherapy combination.
- To determine whether the level of specific gene and/or gene products (genes are genetic
material that allows cells to make proteins such as enzymes) are useful to predict if
this chemotherapy combination will work or not.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute